Philips Releases Toxins Testing Results For Recalled DreamStation Breathing Device

Royal Philips says a first round of testing on its first generation DreamStation has found that the level of volatile organic compounds (VOCs) put off by the recalled device “is not typically anticipated to result in long-term health consequences for patients.”

Royal Philips logo.
• Source: Alamy

Royal Philips says a first round of toxins testing on its DreamStation breathing machine has found that the level of volatile organic compounds (VOCs) put off by the recalled device probably won’t cause long-term health effects for users.

More than 2 million bi-level positive airway pressure (BiPAP), continuous positive airway pressure (CPAP), and other mechanical ventilator devices were...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Recalls

More from Policy & Regulation